However, analysis of a pediatric ALL cohort uniformly treated with GCs and chemotherapy [38] revealed that patients with the BIM deletion did not experience inferior response rates nor poorer clinical outcomes. The gene discussed is BCL2L11; the disease is acute lymphoblastic leukemia.